ONCO Share Price Performance
SEK 1.66
-3.82 (-69.64%)
40.6% undervalued intrinsic discount
SEK 2.80
Fair Value
Price SEK 1.66
AnalystConsensusTarget SEK 2.80
DailyInvestors SEK 2.56
AnalystHighTarget SEK 3.10
Fair ValueSEK 2.80
Share Pricen/a
Oncopeptides AB (publ) Stock Price
- 4 Narratives written by author
- 1 Comments on narratives written by author
- 21 Fair Values set on narratives written by author
ONCO Community Narratives
AN
Fair Value
·Fair Value SEK 2.8 40.6% undervalued intrinsic discount
EU And Japan Expansion Will Leverage Aging Population Trends
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
DA
Fair Value
·Fair Value SEK 2.56 35.0% undervalued intrinsic discount
Oncolytics Biotech: A Beacon of Hope in Cancer Treatment
0users have liked this narrative
1users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value SEK 3.1 46.3% undervalued intrinsic discount
Aging Population And Precision Oncology Will Open New Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Oncopeptides
35.0% undervalued intrinsic discount
Oncolytics Biotech: A Beacon of Hope in Cancer Treatment
View narrativeDA
Published 24 Feb 2025
Oncopeptides
20.8% undervalued intrinsic discount
European Pricing And Regulatory Pressures Will Erode Value
View narrativeAN
Updated 9 Jul
Oncopeptides
46.3% undervalued intrinsic discount
Aging Population And Precision Oncology Will Open New Markets
View narrativeAN
Updated 25 Jun
Oncopeptides
40.6% undervalued intrinsic discount
EU And Japan Expansion Will Leverage Aging Population Trends
View narrativeAN
Updated 29 Apr
Trending Discussion
No trending discussion available.
Recently Updated Narratives
DA
Oncolytics Biotech: A Beacon of Hope in Cancer Treatment
Fair Value: SEK 2.56 35.0% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
ONCO: Expanded Multiple Myeloma Reach Will Drive Future Risk Reward Repricing
Fair Value: SEK 2.1 20.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ONCO: Expanded Multiple Myeloma Indication Will Drive Long-Term Upside
Fair Value: SEK 3.1 46.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Oncopeptides AB (publ) Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 05, 2026
- -0.54
- 96.40%
- -223.81%
- 542.3%
About ONCO
- Founded
- 2000
- Employees
- 69
- CEO
- WebsiteView website
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells. It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma. The company also provides Small Polypeptide based Killer Engagers (SPiKE) platform that is designed to bind to both NK-cells and specific targets on various cancer cells. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
